But this week, the stock jumped again after Amgen issued a strong financial update Tuesday. Its rise helped push up the S&P ...

Amgen stock rose early Wednesday, though the biotech behemoth said the FDA placed one of its obesity treatments on clinical ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

Shares of Amgen (AMGN) fell in after-hours trading after the biotechnology company reported earnings for its fourth quarter ...

Results include $1.2 billion of sales from rare disease products, driven by TEPEZZA, KRYSTEXXA, UPLIZNA, and TAVNEOS. Earnings reflect acquisition-related costs related to the Horizon acquisition.

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...

Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.

Product sales rose 11%, led by 14% volume growth. Products including Repatha, Blincyto and Tezspire all posted at least double digit sales growth, the company said. For the current year, Amgen expects ...

These products underscore Amgen's capacity to seize growth opportunities, particularly in rare disease markets. Additionally, the operating margin expanded to 26.5%, reflecting operational ...